 |
|
|
| |
The TLR8 agonist Selgantolimod modulates Kupffer
cell differentiation status and indirectly impairs
HBV entry into hepatocytes via an IL-6-dependent mechanism
|
| |
| |
EASL 2023 June 21-24 Vienna
Armando Andres Roca Suarez1,2,3, Marie-Laure Plissonnier1,2,3, Xavier Grand1,2,3, Maud Michelet1,2,3, Guillaume Giraud1,2,3, Simon P. Fletcher4, Michel Rivoire5, Barbara Testoni1,2,3, Massimo Levrero1,2,3,6, Fabien Zoulim1,2,3,6
|
| |
|
|
|
|
|
